HCW Biologics wins USPTO patent allowance for HCW9302 use in alopecia areata treatment
HCWB•Phase 1 study remains on track
The company said its Phase 1 dose-escalation study in alopecia areata remains on track to complete in Q4 2026 with no dose-limiting toxicities reported.
Early data from the first two cohorts showed a positive response after a single 3 micrograms/kg monotherapy dose.
USPTO allowance expands protection for HCW9302
HCW Biologics received a USPTO notice of allowance for patent claims covering use of HCW9302 to treat alopecia areata.
The move expands U.S. intellectual property protection for HCW9302, the company’s lead IL-2-based immunotherapy program.
